Preliminary Study of the Clinical Features of the Chemosensitivity Test in Colorectal Cancer

Purpose: Colorectal cancers have been known to be refractory to chemotherapy in the past decades. Re-cently, novel agents have been developed and various data have shown an improved response rate and a survival benefit. However, considerable heterogeneity exists between cancers of the same tissue type, including colorectal cancer. Thus, Individualized chemotherapy that is tailored specifically to the characteristics of the tumor is necessary for an improved clinical outcome. Methods: We evaluate the chemosensitivity of colorectal cancer to standard drugs (5-FU, oxaliplatin, and irinotecan) and to drugs used for other cancers (mitomycin, paclitaxel, and gemcitabine) by using Adenosine-triphosphate-based che-motherapy response assay (ATP-CRA). Results: The de-gree of in-vitro response to a single anticancer medi